HBM notches up another mega deal but is the model sustainable?
The biotech has agreed to sell rights to one of its cancer drugs under development for up to $670 million, adding more fuel to its share price rebound this year…
A blockbuster cancer drug? TYK’s claims go under the microscope
The medicines company released scanty but promising results for an experimental drug just as its shares were joining the Hong Kong Stock Connect scheme Key Takeaways: The drug being developed…
Earnings blow for CSPC Pharma as the state drives a hard bargain
The generic drugs giant has warned of a 26% slide in annual profits after China’s national healthcare system imposed big price cuts on qualifying medicines Key Takeaways: CSPC Pharma…
AstraZeneca could face limited fallout from Chinese tax probe
The drugs giant and one of its top executives are being investigated over business tactics in China, but a potential fine for one alleged offence would not break the bank…
A McDonald’s Valuation Downsize, and New Medical Plan Additions
The value of McDonald's China operation has plunged by more than half in the last year. And 91 companies got their drugs added to China's national health plan By Doug…
NEWS WRAP: AstraZeneca China president assisting in investigation
The British drugmaker said Leon Wang is currently cooperating with an ongoing probe, as media reported the case involved the defrauding of China’s national insurance fund By A. Au…
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
A potential sale of Legend Biotech may carry a 30% to 50% premium, which could generate up to 55.8 billion yuan for Genscript based on its 48% stake in the…
Recent Articles
RELATED ARTICLES
-
AstraZeneca could face limited fallout from Chinese tax probe
AZN.US
-
McKinsey Weighs China Exit, and Shenzhen Rescues Vanke
2202.HK 000002.SHE
-
NEWS WRAP: Profit plunges at JinkoSolar’s main China-listed unit
JKS.US 688223.SHG
